Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
about
Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancerPathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal CellsStrategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin StudyDevelopmental origins of nonalcoholic fatty liver diseaseFibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs).Pathobiology of liver fibrosis: a translational success storyPNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosisBiomarkers of NAFLD progression: a lipidomics approach to an epidemic.CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis.Hepatitis regulation by the inflammasome signaling pathway.Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.Modulation of IKKβ/NF-κB and TGF-β1/Smad via Fuzheng Huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice.Astragalus and Paeoniae radix rubra extract inhibits liver fibrosis by modulating the transforming growth factor‑β/Smad pathway in rats.Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: pleiotropic effects hypothesis.PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.Hepatitis C virus: Morphogenesis, infection and therapy.Treating fatty liver disease by modulating mitochondrial pyruvate metabolism.
P2860
Q26992106-D31C1345-3F03-46BE-98A7-2897BC077CA1Q28071596-69642B36-A34F-4ED6-90E6-706E060BDAD7Q28082065-93A69F21-9142-4D00-9C77-0301B988479CQ30368624-1D477133-CBF6-4851-BD9E-2F0A638F3FAAQ33844787-26B7A5EC-BD24-4DA9-A5B9-47DDEA46BA0BQ34309876-673E2980-3839-43E1-BC53-BE761390863CQ34462733-1656B2F7-9D75-43C7-B678-CD43D99F09B9Q34985968-428E5B40-41D3-49B8-B1AF-814015D5CBD4Q35120968-57C1487A-432C-4398-86AE-1C740DC7CD83Q35692948-1C2AED5A-901C-4F02-AEC6-D21843810B41Q38423384-9A9DE69A-A205-4847-A06D-A28AADA31444Q38802973-0A0F95DD-059E-4069-B2A5-4021A042C597Q40906850-0269D500-0B87-4DEE-ABB5-1B350CF8AAE7Q42074829-F4DF1A32-C812-4B1D-866A-D5EF540159FDQ45947175-2B4B3C20-3406-461A-AE26-608347C5CE87Q47805260-DB61600E-0E1C-4DF3-9E84-EEBC1CE0D0C7Q52661702-A50B3906-361A-402D-9B50-C6D7E848C5B7Q52699083-19497238-CABE-43EE-AD9A-9972D6E252B9
P2860
Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
@en
type
label
Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
@en
prefLabel
Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
@en
P2860
P1476
Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
@en
P2093
Scott L Friedman
P2860
P2888
P356
10.1038/NRGASTRO.2012.256
P407
P577
2013-01-08T00:00:00Z